RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 90 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $1,838,015 | -0.6% | 42,419 | +5.5% | 0.01% | -13.3% |
| Q4 2023 | $1,848,684 | +92.2% | 40,215 | -4.1% | 0.02% | +87.5% |
| Q3 2023 | $961,727 | +39.5% | 41,951 | +0.4% | 0.01% | +33.3% |
| Q2 2023 | $689,167 | +3.3% | 41,793 | +11.8% | 0.01% | 0.0% |
| Q1 2023 | $667,002 | -40.0% | 37,388 | -2.1% | 0.01% | -40.0% |
| Q4 2022 | $1,112,326 | -25.1% | 38,198 | -44.5% | 0.01% | -16.7% |
| Q3 2019 | $1,486,000 | -6.3% | 68,850 | -4.5% | 0.01% | 0.0% |
| Q2 2019 | $1,586,000 | -30.4% | 72,070 | -13.3% | 0.01% | -25.0% |
| Q1 2019 | $2,278,000 | +6.5% | 83,115 | +4.5% | 0.02% | -5.9% |
| Q4 2018 | $2,138,000 | +21.2% | 79,521 | +31.5% | 0.02% | +41.7% |
| Q3 2018 | $1,764,000 | +41.2% | 60,476 | +51.4% | 0.01% | +50.0% |
| Q2 2018 | $1,249,000 | +71.6% | 39,952 | +9.2% | 0.01% | +33.3% |
| Q1 2018 | $728,000 | – | 36,593 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 735,000 | $13,112,400 | 3.93% |
| NEA Management Company, LLC | 2,909,956 | $51,913,615 | 3.59% |
| Frazier Life Sciences Management, L.P. | 2,164,739 | $38,618,944 | 2.80% |
| RA Capital Management | 5,516,067 | $98,406,635 | 2.23% |
| Samsara BioCapital, LLC | 345,293 | $6,160,027 | 1.27% |
| Rock Springs Capital Management LP | 1,597,123 | $28,492,674 | 0.68% |
| Baker Brothers Advisors | 6,498,267 | $115,929,083 | 0.63% |
| HighVista Strategies LLC | 35,478 | $632,928 | 0.52% |
| Nan Fung Group Holdings Ltd | 32,520 | $580,157 | 0.40% |
| GREAT POINT PARTNERS LLC | 97,544 | $1,740,185 | 0.34% |